公开(公告)号：US20240270710A1

公开(公告)日：2024-08-15

申请号：US18289586

申请日：2022-05-06

申请人： PHARMALA BIOTECH INC.

发明人： Tao Xin

IPC分类号： C07D317/60

CPC分类号： C07D317/60

摘要： The present application includes processes for preparing the (R)- or (S)-enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and the (R)- or (S)-enantiomers of N-methyl-1,3-benzodioxolylbutanamine (MBDB) starting with the alkyl esters of 3,4-dihydroxy-L-phenylalanine (L-DOPA) or alkyl esters of 3,4-dihydroxy-L-phenylalanine (D-DOPA), respectively. The present application also includes novel intermediate compounds useful in the preparation of the enantiomers of MDMA and MBDB.

公开(公告)号：US20240325338A1

公开(公告)日：2024-10-03

申请号：US18739924

申请日：2024-06-11

申请人： PharmAla Biotech Inc.

发明人： Harpreet Kaur ,  Tao Xin

IPC分类号： A61K31/335 ,  A61K31/4025 ,  A61P25/00 ,  C07D405/10

CPC分类号： A61K31/335 ,  A61K31/4025 ,  A61P25/00 ,  C07D405/10 ,  C07B2200/07

摘要： The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof




Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy.
The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof:




wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof.
Further included are process preparing a compound of Formula (R)-I or (S)-I.

公开(公告)号：US12042478B2

公开(公告)日：2024-07-23

申请号：US18380423

申请日：2023-10-16

申请人： Pharmala Biotech Inc.

发明人： Harpreet Kaur ,  Tao Xin

IPC分类号： A61K31/335 ,  A61K31/4025 ,  A61P25/00 ,  C07D405/10

CPC分类号： A61K31/335 ,  A61K31/4025 ,  A61P25/00 ,  C07D405/10 ,  C07B2200/07

摘要： The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof.




Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy.
The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof:




wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof.

Further included are process preparing a compound of Formula (R)-I or (S)-I.

公开(公告)号：US20240051947A1

公开(公告)日：2024-02-15

申请号：US18380423

申请日：2023-10-16

申请人： Pharmala Biotech Inc.

发明人： Harpreet Kaur ,  Tao Xin

IPC分类号： C07D405/10 ,  A61P25/00

CPC分类号： C07D405/10 ,  A61P25/00 ,  C07B2200/07

摘要： The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof.




Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy.
The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof:




wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof.
Further included are process preparing a compound of Formula (R)-I or (S)-I.